OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.51 Million Stock Holdings in OrthoPediatrics Corp. (NASDAQ:KIDS)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 25.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 65,292 shares of the company's stock after acquiring an additional 13,270 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.27% of OrthoPediatrics worth $1,513,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of KIDS. Millennium Management LLC acquired a new position in OrthoPediatrics in the fourth quarter valued at approximately $9,798,000. Deutsche Bank AG raised its position in OrthoPediatrics by 57.1% in the fourth quarter. Deutsche Bank AG now owns 14,393 shares of the company's stock worth $334,000 after acquiring an additional 5,233 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of OrthoPediatrics in the fourth quarter valued at $461,000. Northern Trust Corp increased its position in shares of OrthoPediatrics by 0.3% in the fourth quarter. Northern Trust Corp now owns 193,798 shares of the company's stock valued at $4,492,000 after buying an additional 644 shares in the last quarter. Finally, Tudor Investment Corp ET AL increased its position in shares of OrthoPediatrics by 177.5% in the fourth quarter. Tudor Investment Corp ET AL now owns 66,486 shares of the company's stock valued at $1,541,000 after buying an additional 42,526 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.

Wall Street Analyst Weigh In

KIDS has been the topic of a number of analyst reports. Lake Street Capital initiated coverage on OrthoPediatrics in a research note on Monday, April 7th. They set a "buy" rating and a $37.00 price objective on the stock. Piper Sandler reduced their price objective on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Thursday, May 8th. Stifel Nicolaus dropped their target price on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, March 5th. Finally, Truist Financial dropped their price objective on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $35.83.

OrthoPediatrics Stock Down 1.4%

Shares of KIDS stock traded down $0.32 on Monday, reaching $22.75. 8,180 shares of the company's stock traded hands, compared to its average volume of 196,456. The business's 50 day moving average price is $22.86 and its two-hundred day moving average price is $23.95. The company has a market capitalization of $552.53 million, a P/E ratio of -18.50 and a beta of 1.09. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. OrthoPediatrics Corp. has a 12-month low of $20.25 and a 12-month high of $35.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.41 million for the quarter, compared to analyst estimates of $51.68 million. On average, equities analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Insider Activity

In other news, CEO David R. Bailey sold 6,620 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now owns 319,155 shares of the company's stock, valued at $7,934,193.30. This trade represents a 2.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $132,006.60. Following the transaction, the general counsel now owns 110,767 shares of the company's stock, valued at approximately $2,753,667.62. The trade was a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,732 shares of company stock valued at $589,978 over the last 90 days. 32.70% of the stock is owned by company insiders.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.